Expression of Estrogen Receptor and Progesterone Receptor Status In Patients of Carcinoma of Ovary and Carcinoma of Endometrium

Razia Irshad; Ghulam  Haider; Anusha  Hassan; Madiha  Hashmi

doi:10.51253/pafmj.v75iSUPPL-1.6339

Authors

Razia Irshad Department of Medical Oncology of Jinnah Postgraduate Medical Centre, Karachi Pakistan
Ghulam Haider Department of Medical Oncology of Jinnah Postgraduate Medical Centre, Karachi Pakistan
Anusha Hassan Department of Medical Oncology of Jinnah Postgraduate Medical Centre, Karachi Pakistan
Madiha Hashmi Department of Medical Oncology of Jinnah Postgraduate Medical Centre, Karachi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v75iSUPPL-1.6339

Keywords:

Carcinoma, endometrium, estrogen, ovary, progesterone.

Abstract

Objective: To evaluate the expression of estrogen and progesterone receptor status in patients of carcinoma of ovary and carcinoma of endometrium.

Study Design: Cross-sectional study.

Place and Duration of Study: Department of Medical Oncology of Jinnah Postgraduate Medical Centre, Karachi Pakistan, from Feb 2019 to Feb 2020.

Methodology: Seventy females of age 18-70 years with histologically proven diagnosis of ovarian carcinoma or endometrial carcinoma were included in the study. Each patient was interviewed for obtaining demographic details, medical history and presenting symptoms with help of validated questionnaire. Immunohistochemical analysis was performed for confirming estrogen and progesterone receptor expressions.

Results: Out of 72 evaluated patients, ovarian carcinoma was present in 45(62.5%) patients and endometrial carcinoma in 27(37.5%) patients having mean age of 52.6±10.1 (30-69) years. Mean body mass index was 30.4 ± 5.7(18-39) Kg/m2 with obesity in 42(58.3%) patients. Immunohistochemistry showed estrogen receptor positive in 32(71.1%) and 18(66.7%) patients, estrogen receptor negative in 13(28.9%) and 9(33.3%) patients, progesterone receptor positive in 31(68.9%) and 19(70.4%) and progesterone receptor negative in 14(31.1%) and 8(29.6%) patients of ovarian and endometrial carcinoma respectively. Overall it showed higher expression of ER and PR in patients of ovarian and endometrial carcinoma.

Conclusion: The study concludes that approximately two third of patients showed estrogen and progesterone receptor expression in ovarian and endometrial carcinoma. These ER and PR expressions have capability to be utilized as prognostic indicator for ovarian and endometrial carcinoma.

Downloads

Download data is not yet available.

References

Centers for Disease Control and Prevention (CDC). Gynecologic Cancers. U.S. Department of Health & Human Services; 2019. Available at: https://www.cdc.gov/cancer/gynecologic/index.htm [Accessed on 29 April 2021].

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394-424.

International Agency for Research on Cancer (IARC). The Global Cancer Observatory (GCO). IARC; 2020. Available at: https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=2&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=1&include_nmsc_other=1 [Accessed on 29 April 2021].

Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019 Apr 30; 11:287-299.

Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al.,. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018 Jul; 68(4): 284-96.

World Health Organization. The Global Cancer Observatory: Pakistan. Geneva: World Health Organization; 2018. Available at: https://gco.iarc.fr/today/data/factsheets/populations/586-pakistan-fact-sheets.pdf [Accessed on 29 April 2021].

Tkalia IG, Vorobyova LI, Svintsitsky VS, Nespryadko SV, Goncharuk IV, Lukyanova NY, et al.,. Clinical significance of hormonal receptor status of malignant ovarian tumors. Exp Oncol. 2014: 36(2): 125-33.

Ciucci A, Zannoni GF, Travaglia D, Petrillo M, Scambia G, Gallo D. Prognostic significance of the estrogen receptor beta (ERβ) isoforms ERβ1, ERβ2, and ERβ5 in advanced serous ovarian cancer. Gynecol Oncol. 2014; 132(2): 351-9.

Yang S, Thiel KW, Leslie KK. Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab. 2011 Apr 1;22(4): 145-52.

Anwar M, Asif M, Ahmed R, Khadim MT, Mansur H, Ahmed R. Analysis of estrogen receptor (ER) and progestrone receptor (PR) expression in surface epithelial tumors of ovary and its correlation with their clinical stage. Pak Arm For Med J. 2018 Oct 31; 68(5): 1121-25.

Qureshi A, Pervez S. Allred scoring for ER reporting and it's impact in clearly distinguishing ER negative from ER positive breast cancers. J Pak Med Assoc. 2010; 60(5): 350.

Chaudhry S, Rajani H, Hussain R, Naqvi A. Ovarian cancer: most frequently seen gynaecological malignancy in Ziauddin Hospital, North Nazimabad. Pak J Med Dent. 2019; 8(4): 37-42.

Chaudry S, Sadaf T, Butt S, Syed AA, Siddiqui N. Clinicopathological characteristics of patients with synchronous primary ovarian and endometrial cancers. J Cancer Allied Spec. 2016; 2(2): 4.

Mohyuddin S, Sultana NI, Butt KA, Mohyuddin A. Patterns of gynaecological malignancies at a tertiary care hospital. Pak J Med Health Sci. 2012 Jan 1; 6(1) : 47-51.

Jamal S, Mamoon N, Mushtaq S, Luqman M, Moghal S. The pattern of gynecological malignancies in 968 cases from Pakistan. Ann Saudi Med. 2006 Sep; 26(5) : 382-4.

Tanvir I, Riaz S, Hussain A, Mehboob R, Shams MU, Khan HA. Hospital-based study of epithelial malignancies of endometrial cancer frequency in Lahore, Pakistan, and common diagnostic pitfalls. Patholog Res Int. 2014; 2014: 179384.

Fatima I, Rashid MN, Ahmed F, Soomro AM. Occurrence of different types of endometrial carcinoma in hysterectomy specimens from different hospitals in Karachi, Pakistan. Am J Life Sci. 2015; 3(3) : 143-6.

Wang C, Tran DA, Fu MZ, Chen W, Fu SW, Li X. Estrogen receptor, progesterone receptor, and HER2 receptor markers in endometrial cancer. J Cancer. 2020 Jan 16; 11(7) : 1693-701.

Tomica D, Ramic S, Danolic D, Susnjar L, Peric-Balja M, Puljiz M. Impact of oestrogen and progesterone receptor expression in the cancer cells and myometrium on survival of patients with endometrial cancer. J Obstet Gynaecol. 2018 Jan; 38(1) : 96-102.

Waqar S, Khan SA, Sarfraz T, Waqar S. Expression of estrogen receptors (ER), progesterone receptors (PR) and HER-2/neu receptors in endometrial carcinoma and their associations with